Imv Incis A Clinical Stage Biopharmaceutical Company Based In Dartmouthcanadaestablished In 2000The Companyformerly Known As Immunovaccine Inc Focuses On Developing Immunotherapies And Vaccines Utilizing Its Proprietary Dpx Technology Platformthis Platform Is Designed To Program Immune Cells In Vivogenerating Targeted T Cell Responses For Effective Treatment Against Cancer And Infectious Diseases Imv S Lead Productmaveropepimut Sdpx Survivac Is A T Cell Immunotherapy Currently In Phase Ii Trials For Various Cancersincluding Diffuse Large B Cell Lymphoma And Ovarian Cancerthe Company Is Also Advancing Other Therapiessuch As Dpx Surmage For Bladder Cancer And Vaccine Candidates For Covid 19 And Respiratory Syncytial Virusimv Collaborates With Merck To Explore The Combination Of Maveropepimut S With Keytrudaafor Specific Cancer Treatments
| Company Name | Immunovaccine Technologies Inc |
| Country |
Canada
|
| Address | N/A |
| Telephone | N/A |
| N/A |
United States